Table 3 Survival analysis of clinicopathologic variables for overall survival (OS) and progression-free survival (PFS) in the adult group.

Sex

0.29

0.17

    Male

89.4 (0.06)

71.3 (0.10)

69.2 (0.09)

58.0 (0.09)

    Female

100

78.5 (0.07)

85.5 (0.06)

67.3 (0.08)

Symptom

—^*

—^*

    Symptomless

97.3 (0.03)

78.5 (0.08)

83.9 (0.06)

68.2 (0.08)

    Haematuria

90.0 (0.07)

78.5 (0.10)

72.0 (0.10)

59.7 (0.11)

Abdominal mass

—^*

—

—

—

    Flank pain

100

51.4 (0.19)

72.7 (0.13)

51.9 (0.16)

Laterality

0.80

0.78

    Left

93.6 (0.04)

71.8 (0.10)

78.5 (0.07)

67.9 (0.09)

    Right

97.3 (0.03)

78.2 (0.07)

78.9 (0.07)

60.2 (0.09)

Operation

0.78

0.16

    RN

95.6 (0.03)

75.9 (0.07)

74.3 (0.06)

57.5 (0.08)

    NSS

95.8 (0.04)

72.6 (0.13)

87.5 (0.07)

75.4 (0.10)

pT stage

<0.01

<0.01

    T1/T2

100

90.0 (0.05)

92.4 (0.04)

82.4 (0.06)

    T3/T4

82.4 (0.09)

34.0 (0.13)

36.7 (0.12)

0

Nuclear grade

0.64

0.50

    1/2

95.3 (0.03)

75.6 (0.07)

79.7 (0.06)

67.1 (0.07)

    3/4

96.0 (0.04)

74.6 (0.10)

77.2 (0.08)

53.6 (0.13)

AJCC stage

<0.01

<0.01

    I/II

100

91.9 (0.05)

93.7 (0.04)

88.9 (0.05)

    III/IV

85.7 (0.08)

38.5 (0.12)

46.6 (0.11)

0

Local lymph node metastasis

<0.01

<0.01

    LN+

84.2 (0.08)

40.3 (0.13)

40.0 (0.11)

0

    LN−

100

89.1 (0.05)

93.9 (0.03)

87.3 (0.05)

Vena cava tumour thrombosis

<0.01

<0.01

    Positive

88.9 (0.11)

22.2 (0.14)

11.1 (0.11)

0

    Negative

96.6 (0.02)

85.1 (0.05)

88.6 (0.04)

72.8 (0.06)

Adjuvant therapy

<0.01

<0.01

    None

95.7 (0.04)

87.7 (0.09)

95.7 (0.04)

85.2 (0.08)

    Immunotherapy

100

90.5 (0.07)

86.4 (0.06)

82.7 (0.07)

    Targeted therapy

88.9 (0.07)

43.8 (0.12)

44.4 (0.11)

11.1 (0.07)

Tumour boundary

0.35

0.02

    Clear

97.6 (0.02)

80.0 (0.08)

88.0 (0.05)

71.1 (0.08)

    Unclear

92.6 (0.05)

68.6 (0.09)

65.2 (0.09)

50.5 (0.10)